Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| CJC-1295 (with DAC) | Pentadeca Arginate (PDA) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 2 mg administered once weekly via subcutaneous injection. | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection. |
| Timing | Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release. | Administer on an empty stomach. Inject near site of injury for localized effect. |
| Cycle Duration | 12-24 week cycles with 4-8 week breaks between cycles. | 4-12 weeks depending on therapeutic target. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analog with four amino acid substitutions rendering it resistant to DPP-IV proteolytic inactivation. The DAC moiety covalently binds to endogenous serum albumin via a disulfide bond after injection, extending half-life to 5.8-8.1 days. It stimulates pulsatile GH release from anterior pituitary somatotrophs through GHRH receptor activation, producing dose-dependent 2-10 fold increases in plasma GH for 6+ days and 1.5-3 fold IGF-1 elevations for 9-11 days per injection.
Research indicates 2 mg administered once weekly via subcutaneous injection.
Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.
12-24 week cycles with 4-8 week breaks between cycles.
Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
Administer on an empty stomach. Inject near site of injury for localized effect.
4-12 weeks depending on therapeutic target.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →